Search

Displaying results 1611 - 1620 of 10000 in total
  1. Drug

    Podophyllin

    go.drugbank.com/drugs/DB09094
    Approved

    Podophyllin is the principal active component. Podophyllin arrests mitosis in metaphase. … Podophyllin is a resin extracted from the roots of _Podophyllum peltatum_ (American mandrake) and _Podophyllum emodi_, which contains numerous compounds, amongst which is podophyllin (as well as the drug

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.

    Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADET
  3. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783] … Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin.

    Categories: Drugs Used in Hereditary Angioedema
  4. Drug

    Mometasone

    go.drugbank.com/drugs/DB00764
    ApprovedInvestigational

    Mometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.

  5. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. … [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity.

  6. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections. … [A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].

  7. Drug

    Gabapentin

    go.drugbank.com/drugs/DB00996
    ApprovedInvestigational

    Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. … unlikely to participate in pharmacokinetic drug interactions.

    Mixtures: Lipritin II, Prilopentin -II
  8. Drug

    Streptomycin

    go.drugbank.com/drugs/DB01082
    ApprovedInvestigationalVet approved

    Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s. … adjunctive treatment in cases of multi-drug resistant tuberculosis.

  9. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the … Bromelain is consequently a composite mixture of several different endopeptidases that can facilitate many different reactions with many different substrates.

  10. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    therapy developed by Mayne Pharma in 1992. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.

    Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200